Revolution Medicines Inc拟发行7.5亿美元普通股及2.5亿美元2033年到期可转换优先票据

美股速递
Apr 14

生物制药公司Revolution Medicines Inc宣布启动双重融资计划,拟通过公开发行募集总额10亿美元资金。该方案包括发行价值7.5亿美元的普通股,同时配售2.5亿美元于2033年到期的可转换优先票据。此次融资将用于推进其肿瘤靶向治疗管线的临床开发,并加强企业运营资本储备。

可转换票据持有人有权在特定条件下将债务转换为公司普通股,这种融资结构既能为企业提供长期资金支持,又可能降低未来股权稀释风险。市场分析师指出,大规模融资动作显示公司正加速核心项目的商业化布局,尤其在RAS抑制剂领域的技术突破备受行业关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10